FSD Pharma Inc. (HUGE) News
Filter HUGE News Items
HUGE News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
HUGE News Highlights
- HUGE's 30 day story count now stands at 6.
- Over the past 8 days, the trend for HUGE's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about HUGE are LAB, LINK and MO.
Latest HUGE News From Around the Web
Below are the latest news stories about FSD PHARMA INC that investors may wish to consider to help them evaluate HUGE as an investment opportunity.
InvestmentPitch Media Video Discusses FSD Pharma’s Cost Award of $2.81 Million from Dr. Raza Bokhari in an Arbitration SettlementVANCOUVER, British Columbia, May 16, 2023 (GLOBE NEWSWIRE) -- FSD Pharma Inc. (NASDAQ:HUGE) (CSE:HUGE) (FSE:0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, has been awarded approximately $2.81 million Canadian in an arbitration settlement. A Media Snippet accompanying this announcement is available by clicking on the image or link below: For mo |
FSD Pharma Announces Receipt of Court Action and Update on Spin-Out and DistributionTORONTO, May 12, 2023--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, announces that a complaint was filed on May 1, 2023 in the United States District Court for the Southern District of Florida by GBB Drink Lab, Inc. ("GBB") against FSD Pharma and its subsidiary, |
FSD Pharma Awarded $2.81 Million in Cost Awards From Dr. Raza BokhariTORONTO, May 11, 2023--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, today announced that in a cost award decision (the "Costs Award") dated May 6, 2023, the Honourable J. Douglas Cunningham, K.C. ("Justice Cunningham") ruled in favor of FSD Pharma, awarding the |
FSD Pharma Completes Dosing of First Cohort in Phase I Clinical Trial of Lucid-MS, a New Drug Candidate for the Treatment of Multiple Sclerosis: Safety Review Committee Recommends Commencing Dosing of Second CohortTORONTO, May 10, 2023--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, today announced the completion of dosing the first cohort of patients in the Company’s Phase I clinical trial of Lucid-21-302 ("Lucid-MS"). The clinical trial (ClinicalTrials.gov Identifier: NCT |
Sidoti's Micro-Cap Virtual May ConferenceSidoti & Company, LLC has released the presentation schedule and weblinks for its two-day May Micro-cap Conference taking place Wednesday and Thursday, May 10-11, 2023. Presentation schedule is subject to change, please visit www.sidoti.com/events for the most updated version and webinar links. |
FSD Pharma to Present at Sidoti Virtual Investor Conference May 10-11TORONTO, May 08, 2023--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, today announced Mr. Zeeshan Saeed, President and Executive Co-Chairman, and Dr. Lakhsmi Kotra, Executive Director and CEO Lucid Psycheceuticals, will present and host one-on-one meetings with in |
FSD Pharma Achieves Milestone in Completion of Dosing of Sentinel Subjects in First-in-Human Clinical Trial of Lucid-MS (Lucid-21-302) for Multiple SclerosisTORONTO, April 17, 2023--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, today announced completion of the first-in-human ("FIH") sentinel dosing of Lucid-21-302 ("Lucid-MS") in the Company’s Phase I clinical trial evaluating its novel drug candidate as an orally-a |
IIROC Trade Resumption - HUGETrading resumes in: |
IIROC Trading Halt - HUGEThe following issues have been halted by IIROC: |
FSD Pharma Announces Plan to Spin-Out Subsidiary as Distribution to Shareholders; Shareholder Meeting Scheduled for June 29, 2023TORONTO, April 12, 2023--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, is pleased to announce it intends to complete a spin-out transaction via a plan of arrangement (the "Plan of Arrangement") under the Business Corporations Act (Ontario) (the "Spin-out Transact |